Herceptin Patent Expiry to Pave Way for Breast Cancer Generics
Herceptin, the breast cancer drug will face patent expiration in 2014 and 2019 for Europe and US respectively. With regard to this, many generic manufacturers plan to acquire a significant share of Herceptin’s market. Several companies including Amgen, Pfizer and Novartis have already joined the race to develop a generic version of Herceptin. Similarly, many of the world’s largest selling cancer drugs are scheduled to lose patent protection in the coming years. This will allow the generic manufacturers to replicate...
View full press release